

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **August 7, 2020**

**LEXARIA BIOSCIENCE CORP.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction of  
incorporation)

**000-52138**

(Commission File Number)

**20-2000871**

(IRS Employer Identification No.)

**100 – 740 McCurdy Road, Kelowna, BC Canada**

(Address of principal executive offices)

**V1X 2P7**

(Zip Code)

Registrant's telephone number, including area code **(250) 765-6424**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 7.01 Regulation FD Disclosure**

Lexaria Bioscience Corp. has published an updated company fact sheet. A copy of the fact sheet is attached as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

**Item 9.01 Financial Statements and Exhibits**

[99.1](#) [Lexaria Bioscience Corp. Fact Sheet](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LEXARIA BIOSCIENCE CORP.**

Date: August 7, 2020

By: /s/ Chris Bunka  
**Chris Bunka**  
CEO, Principal Executive Officer



# Lexaria Bioscience Corp.

OTCQX:LXRP | CSE:LXX

## INVESTOR CONTACT

Phone: 866.221.3341 IR@lexariabioscience.com

## DRUG DELIVERY PLATFORM INNOVATOR

Lexaria Bioscience Corp's. (OTCQX: LXRP) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1-2 hours to 15-20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles, and oral products and to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, please visit [www.lexariabioscience.com](http://www.lexariabioscience.com).

### Lexaria Bioscience Corp. (OTCQX: LXRP)

Clinically proven, fast acting, less expensive & more effective oral drug delivery:

- Antivirals (COVID-19, infectious diseases); Oral Nicotine; NSAIDs (Ibuprofen, Aspirin); Cannabinoids; Fat-Soluble Vitamins (A,D,E,K); PDE5 Inhibitors (Viagra, Cialis); Hormones (Estrogen, Testosterone)
- Close collaboration with largest R&D organization in Canada, the National Research Council, since January 2017

### DehydraTECH™

- Patented formulation and dehydration processing method changes how the body detects and absorbs drugs orally
- Faster onset/offset and higher bioavailability in capsules, foods, liquids, mixable powders, etc.
- 16 patents granted (>60 pending) covering method-of-use, composition-of-matter and medical treatment claims



✓Speeds up onset



✓Increases bioavailability



✓Improves drug potency



✓Lower dosage



✓Lower cost

### Patented DehydraTECH Process (Simplified)



**1** Combine Active Pharmaceutical Ingredient "API" with Fatty Acid Oil



**2** Apply to food/carrier particles



**3** Perform dehydration synthesis procedure



**4** Render as powder or liquid for use in desired final form factor

### Recent Highlights

- In July 2020, the Company successfully completed Phase I R&D program with Altria Ventures Inc. for oral forms of nicotine delivery utilizing its patented DehydraTECH technology
- Applied for NIH grant for COVID-19 therapy studies and received new expanded Health Canada License
- Closed \$2,039,228 private placement
- Filed new patent utilizing DehydraTECH technology for treatment of infectious diseases including COVID-19

|                 |               |          |                    |            |                   |
|-----------------|---------------|----------|--------------------|------------|-------------------|
| PRICE           | 52-WK. RANGE  | AVG. VOL | SHARES OUTSTANDING | MARKET CAP | INSIDER OWNERSHIP |
| \$0.39 (8/6/20) | \$0.22-\$1.00 | 103K     | 89.5M              | \$32.3M    | 21%               |

Lexaria Bioscience Corp. - #100-740 McCurdy Road - Kelowna, BC, V1X2P7 - [www.lexariabioscience.com](http://www.lexariabioscience.com)  
Price and volume quotes from OTCMarkets and other sources

## Key Growth Drivers

- The global controlled release drug delivery market is expected to reach \$69.8B in 2027, and the global drug delivery system market is estimated to reach \$900B by 2025, according to Grand View Research and Transparency Market Research. Lexaria plans to disrupt the Global Tobacco Market forecasted to reach \$1.08 Trillion in 2027 by Grandview Research;
- Investigation underway for COVID-19 applications – many developments expected throughout 2020;
- Opportunity to significantly accelerate and expand upon COVID-19 research program;
- Disruptive drug delivery technology with multiple opportunities for success in antivirals, nicotine, cannabinoids, hormones, other;
- Established revenue generating commercial partnerships for other APIs of interest; additional DehydraTECH transactions expected through 2020;
- Major US exchange uplist program underway.


## Lexaria Nicotine LLC (Majority-Owned)

- Oral nicotine products to disrupt the \$990 billion global nicotine market
- Altria Group international license rights for undisclosed royalty
- Also in discussions with other global tobacco and pharmaceutical companies to use DehydraTECH for oral nicotine products internationally



## Lexaria Pharmaceutical Corp. (Wholly-Owned)

- Programs commenced to prove delivery effectiveness in antiviral therapies for SARS diseases (incl. COVID-19) and other infectious diseases



## Lexaria Hemp Corp. (Wholly-Owned)

- Clinically proved to increase rate and extent of orally ingested CBD
- (<https://www.ncbi.nlm.nih.gov/pubmed/31512143>)
- FDA has begun to engage Congress on rulemaking for CBD dietary supplement commercialization in the U.S.



## MANAGEMENT



### Chris Bunka, Chairman & CEO

- Launched several successful private and public companies since the late 1980's
- Extensive experience in the capital markets, corporate governance, M&A and finance
- Named inventor on multiple patent innovations



### John Docherty, M.Sc., President & Director

- Specialist in development of drug delivery technologies
- Former President and COO of Helix BioPharma Corp. (TSX: HBP)
- Named inventor on multiple issued and pending patents
- Pharmacologist and toxicologist

Disclaimer: This fact sheet includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. State-ments which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for participation and/or financing, com-petitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current infor-mation and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities available on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov](http://www.sec.gov), and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This fact sheet is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes. No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease.